A detailed history of Metis Global Partners, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Metis Global Partners, LLC holds 97,498 shares of ABBV stock, worth $17.1 Million. This represents 0.61% of its overall portfolio holdings.

Number of Shares
97,498
Previous 95,326 2.28%
Holding current value
$17.1 Million
Previous $16.4 Million 17.76%
% of portfolio
0.61%
Previous 0.57%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$163.84 - $199.33 $355,860 - $432,944
2,172 Added 2.28%
97,498 $19.3 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $192,868 - $225,226
1,246 Added 1.32%
95,326 $16.4 Million
Q1 2024

May 06, 2024

SELL
$159.82 - $182.1 $131,851 - $150,232
-825 Reduced 0.87%
94,080 $17.1 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $1.75 Million - $1.97 Million
12,688 Added 15.43%
94,905 $14.7 Million
Q3 2023

Nov 07, 2023

BUY
$133.59 - $154.65 $1.52 Million - $1.76 Million
11,382 Added 16.07%
82,217 $12.3 Million
Q2 2023

Aug 07, 2023

SELL
$132.51 - $164.9 $109,055 - $135,712
-823 Reduced 1.15%
70,835 $9.54 Million
Q1 2023

May 08, 2023

BUY
$144.61 - $166.54 $2.6 Million - $3 Million
18,008 Added 33.57%
71,658 $11.4 Million
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $2.65 Million - $3.18 Million
19,164 Added 55.57%
53,650 $8.68 Million
Q3 2022

Nov 08, 2022

SELL
$134.21 - $153.93 $41,068 - $47,102
-306 Reduced 0.88%
34,486 $4.63 Million
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $611,583 - $777,522
4,444 Added 14.64%
34,792 $5.33 Million
Q1 2022

May 03, 2022

BUY
$131.98 - $163.75 $1.65 Million - $2.05 Million
12,539 Added 70.41%
30,348 $4.92 Million
Q4 2021

Feb 11, 2022

BUY
$107.43 - $135.93 $1.91 Million - $2.42 Million
17,809 New
17,809 $2.41 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Metis Global Partners, LLC Portfolio

Follow Metis Global Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metis Global Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Metis Global Partners, LLC with notifications on news.